ID22975A - Metode dan komposisi untuk memodulasi respons terhadap kortikosteroid - Google Patents

Metode dan komposisi untuk memodulasi respons terhadap kortikosteroid

Info

Publication number
ID22975A
ID22975A IDW991185A ID991185A ID22975A ID 22975 A ID22975 A ID 22975A ID W991185 A IDW991185 A ID W991185A ID 991185 A ID991185 A ID 991185A ID 22975 A ID22975 A ID 22975A
Authority
ID
Indonesia
Prior art keywords
corticosteroids
compositions
methods
modulate response
modulate
Prior art date
Application number
IDW991185A
Other languages
English (en)
Inventor
Les Sekut
Adam Carter
Tariq Ghayur
Subhashis Banerjee
Daniel E Tracey
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/820,692 external-priority patent/US6054487A/en
Application filed by Basf Ag filed Critical Basf Ag
Publication of ID22975A publication Critical patent/ID22975A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IDW991185A 1997-03-18 1998-03-12 Metode dan komposisi untuk memodulasi respons terhadap kortikosteroid ID22975A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/820,692 US6054487A (en) 1997-03-18 1997-03-18 Methods and compositions for modulating responsiveness to corticosteroids
US1634698A 1998-01-30 1998-01-30

Publications (1)

Publication Number Publication Date
ID22975A true ID22975A (id) 1999-12-23

Family

ID=26688484

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW991185A ID22975A (id) 1997-03-18 1998-03-12 Metode dan komposisi untuk memodulasi respons terhadap kortikosteroid

Country Status (20)

Country Link
EP (1) EP0998300A1 (id)
JP (1) JP2002504091A (id)
KR (1) KR20000076420A (id)
CN (1) CN1269722A (id)
AU (1) AU734756B2 (id)
BG (1) BG103808A (id)
BR (1) BR9810409A (id)
CA (1) CA2282845A1 (id)
DE (1) DE998300T1 (id)
ES (1) ES2146192T1 (id)
HU (1) HUP0104439A3 (id)
ID (1) ID22975A (id)
IL (1) IL131815A0 (id)
NO (1) NO994506L (id)
NZ (1) NZ337769A (id)
PL (1) PL336464A1 (id)
SI (1) SI20110A (id)
SK (1) SK122199A3 (id)
TR (1) TR199902615T2 (id)
WO (1) WO1998041232A2 (id)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US6830751B1 (en) 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
AR015966A1 (es) * 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
ATE274920T1 (de) * 1997-10-31 2004-09-15 Wyeth Corp Verwendung von anti-il-12 antikörpern bei transplantationsabstossungen
EP1516630A3 (en) * 1997-10-31 2006-05-03 Wyeth Use of anti-il-12 antibodies in transplantation rejection
WO1999025737A1 (en) * 1997-11-19 1999-05-27 Tanox Pharma B.V. Compositions and methods for treatment of autoimmune diseases, using a monoclonal antibody to the interleukin-12 beta2-chain
EP1076563B1 (en) * 1998-03-16 2005-05-11 Cytovia, Inc. Dipeptide caspase inhibitors and the use thereof
CA2355345A1 (en) * 1998-11-27 2001-06-28 Technion Research & Development Foundation Ltd. Interferon gamma inducing factor based vaccine and use of same for protective immunity against multiple sclerosis
EP1137766B1 (en) * 1998-12-09 2005-09-28 Protein Design Labs, Inc. Use of il-12 antibodies to treat psoriasis
DE60030097T2 (de) 1999-03-16 2007-03-08 Cytovia, Inc., San Diego Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
DE19915465A1 (de) * 1999-04-06 2000-10-19 Apotech Res & Dev Ltd Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten
JP2002541237A (ja) 1999-04-09 2002-12-03 サイトビア インコーポレイテッド カスパーゼインヒビターおよびその使用
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
CN1235875C (zh) 1999-08-27 2006-01-11 西托维亚公司 取代的α－羟基酸天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途
WO2001019373A2 (en) * 1999-09-17 2001-03-22 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
TWI373343B (en) 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using
JP2003535148A (ja) * 2000-06-06 2003-11-25 グラクソ グループ リミテッド 癌の治療方法
AU7250301A (en) * 2000-06-22 2002-01-02 Willy Ben Moussa Ben Mohammed Use of glucocorticosteroids for producing a medicament to treat oligotrichia
US20020025317A1 (en) * 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
WO2002022127A1 (en) * 2000-09-13 2002-03-21 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
ES2295332T3 (es) * 2001-01-29 2008-04-16 Laboratoires Serono Sa Uso de inhibidores de il-18 para el tratamiento y/o prevencion de cardiopatias.
MXPA03010575A (es) * 2001-05-16 2005-03-07 Yeda Res & Dev Uso de inhibidores de il-08 para el tratamiento o prevencion de sepsis.
MY143582A (en) 2001-06-26 2011-05-31 Amgent Fremont Inc Antibodies to opgl
MXPA04003266A (es) * 2001-10-05 2004-07-08 Combinatorx Inc Combinaciones para el tratamiento de desodrdenes inmuno-inflamatorios.
JP2003342196A (ja) * 2002-05-31 2003-12-03 Mukku:Kk 静脈注射用組成物、その製造法およびその製剤
WO2004030618A2 (en) * 2002-09-24 2004-04-15 Combinatorx, Incorporated Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
AU2003263717A1 (en) * 2002-09-25 2004-04-19 Astrazeneca Ab A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
CA2566877A1 (en) * 2004-05-17 2005-11-24 Keio University Medicinal composition and therapeutic method
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
WO2006009114A1 (ja) * 2004-07-16 2006-01-26 Atsuo Sekiyama Ｉｌ－１８レセプターアンタゴニスト、および当該アンタゴニストを含む薬学的組成物
CA2584169A1 (en) * 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. Remedies/preventives for chronic skin disease
ES2384641T3 (es) 2005-07-14 2012-07-10 Lithera, Inc. Formulación lipolítica que potencia la liberación mantenida para el tratamiento localizado del tejido adiposo
PL2077830T3 (pl) * 2006-10-17 2013-04-30 Lithera Inc Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
AU2008205512B2 (en) 2007-01-16 2014-06-12 Abbvie Inc. Methods for treating psoriasis
MX2009010361A (es) 2007-03-29 2009-10-16 Abbott Lab Anticuerpos il-12 anti-humanos cristalinos.
KR20100126515A (ko) 2008-03-18 2010-12-01 아보트 러보러터리즈 건선의 치료방법
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
GEP201606551B (en) 2010-11-24 2016-10-10 Novamedica Llc Selective, lipophilic, and long-acting beta agonists monotherapeutic formulations tions and methods for cosmetic treatment of adiposity and contour bulging
WO2015063669A1 (en) 2013-10-30 2015-05-07 Wockhardt Limited Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
JP2024506384A (ja) 2021-02-10 2024-02-13 イオリクス セラピューティクス，インコーポレーテッド ロフルミラストの眼科的送達方法
CA3231766A1 (en) * 2021-09-22 2023-03-30 Elizabeth W. JEFFORDS Methods of treating ocular inflammatory diseases
WO2024215900A2 (en) * 2023-04-12 2024-10-17 The Board Of Trustees Of The University Of Illinois Agonists of small heterodimer partner for cancer therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
EP0416950B1 (en) * 1989-09-08 1993-08-11 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
MX9304585A (es) * 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
EA000889B1 (ru) * 1995-04-14 2000-06-26 Глаксо Веллкам Инк. Дозирующий ингалятор дипропионата беклометазона

Also Published As

Publication number Publication date
EP0998300A1 (en) 2000-05-10
NZ337769A (en) 2002-09-27
WO1998041232A2 (en) 1998-09-24
CA2282845A1 (en) 1998-09-24
NO994506L (no) 1999-11-17
PL336464A1 (en) 2000-06-19
JP2002504091A (ja) 2002-02-05
CN1269722A (zh) 2000-10-11
ES2146192T1 (es) 2000-08-01
AU734756B2 (en) 2001-06-21
BG103808A (en) 2000-07-31
BR9810409A (pt) 2000-08-22
AU6760498A (en) 1998-10-12
SK122199A3 (en) 2000-12-11
DE998300T1 (de) 2001-03-01
HUP0104439A2 (hu) 2002-04-29
HUP0104439A3 (en) 2002-08-28
NO994506D0 (no) 1999-09-17
TR199902615T2 (xx) 2000-03-21
KR20000076420A (ko) 2000-12-26
IL131815A0 (en) 2001-03-19
SI20110A (sl) 2000-06-30
WO1998041232A3 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
ID22975A (id) Metode dan komposisi untuk memodulasi respons terhadap kortikosteroid
ID17437A (id) Metoda dan komposisi untuk membuat kulit terang
ID22389A (id) Komposisi dan metode untuk menurunkan hipertensi okuler
ID19588A (id) Ester dan amida heterosiklik
ID21935A (id) Proses dan komposisi pewarna rambut
ID20400A (id) Komposisi dan metoda untuk menghambat penuaan akibat cahaya pada kulit
ID24524A (id) Kombinasi penghambat reduktase aldosa dan penghambat fosforilase glikogen
BR9608857A (pt) Composição líquida e detergente líquida
FI972496L (fi) Fusariumisolaatti ja siitä johdettuja lipaaseja, kutinaaseja ja entsyymikoostumuksia
ID23953A (id) Asam 5-alkil-2-arilaminofenilasetat dan turunannya
FI962932A0 (fi) Ankkuriproteiinifunktion modulaattoreita
ID24828A (id) Komposisi-komposisi farmasi dari tizoksianida dan nitazoksanida
ID30135A (id) Komposisi-komposisi dan metode-metode untuk mengontrol serangga-serangga
ID17233A (id) Metode dan [peralatan untuk mengontrol tangki tangki pengental penjernih dan pengendapan
ID18456A (id) Produksi-bersama 6-aminokapronitril dan heksametilenadiamina
ID16889A (id) Senyawa turunan alkilaminobenzotiazol dan benzoksazol
FR2772599B1 (fr) Composition cosmetique et ses utilisations
ID20911A (id) Pak rokok serta metode dan peralatan untuk membuat pak rokok tersebut
NO20002279D0 (no) Sammensetninger av lipidsenkende midler
ID24463A (id) Metode meningkatkan ketersediaan hayati feksofenadin dan turunan-turunannya
ID25848A (id) Komposisi-komposisi dan metode-metode herbisida sinergis
FR2772608B1 (fr) Composition cosmetique et ses utilisations
ID21862A (id) Komposisi-komposisi insektisida dan mitisida
NO975974D0 (no) Komponenter av pulverformig væske- og rensemiddel
EP0820502A4 (en) DETERSIVE COMPOSITIONS COMPRISING NON-IONIC POLYSACCHARIDE ETHERS AND LIPASES